References
- AltarescuGHillSWiggsE2001The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s diseaseJ Pediatr1385394711295718
- BakerMPJonesTD2007Identification and removal of immunogenicity in therapeutic proteinsCurr Opin Drug Discov Devel1021927
- BanikazemiMBultasJWaldekS2007Agalsidase-beta therapy for advanced Fabry disease: a randomized trialAnn Intern Med146778617179052
- BarbeyFBrakchNLinhartA2006Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid depositionArterioscler Thromb Vasc Biol268394416469946
- BarbeyFBrakchNLinhartA2006Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry diseaseActa Paediatr Suppl9563816720468
- BasiSLewisJB2006Microalbuminuria as a target to improve cardiovascular and renal outcomesAm J Kidney Dis479274616731288
- BerthiaumeJTDavisJTairaDA2007A managed care organization’s use of integrated health management to improve secondary prevention of coronary artery diseaseAm J Manag Care13142717335357
- BigazziRBianchiSNenciR1995Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuriaJ Hum Hypertens9827338576899
- BreunigFWeidemannFStrotmannJ2006Clinical benefit of enzyme replacement therapy in Fabry diseaseKidney Int6912162116609685
- CaiSRXuGBecker-HapakM2006The kinetics and tissue distribution of protein transduction in miceEur J Pharm Sci273111916376528
- CampeseVMParkJ2007HMG-CoA reductase inhibitors and the kidneyKidney Int7112152217495867
- ClarkeJT2007Narrative review: Fabry diseaseAnn Intern Med1464253317371887
- ClarkeJTRWestMLBultasJ2007Pharmacokinetics and pharmacodynamics of agalsidase alfa used for enzyme replacement therapy of Fabry diseaseGenetics in Medicine9504917700388
- CloseLElliottP2007Optimization of concomitant medication in Fabry cardiomyopathyActa Paediatr Suppl9681317391449
- CoppoRD’AmicoG2005Factors predicting progression of IgA nephropathiesJ Nephrol185031216299675
- EllederMBradovaVSmidF1990Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathyVirchows Arch A Pathol Anat Histopathol417449552173254
- ElliottPMKindlerHShahJS2006Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase AHeart923576016085718
- EngCMFletcherJWilcoxWR2007Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry RegistryJ Inherit Metab Dis301849217347915
- EngCMGuffonNWilcoxWR2001Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s diseaseN Engl J Med34591611439963
- FerrariP2007Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney diseaseNephrology (Carlton)1281917295666
- GermainDPWaldekSBanikazemiM2007Sustained, long-term renal stabilization after 54 months of agalsidase Beta therapy in patients with fabry diseaseJ Am Soc Nephrol1815475717409312
- GoldKFPastoresGMBottemanMF2002Quality of life of patients with Fabry diseaseQual Life Res113172712086117
- GuptaSRiesMKotsopoulosS2005The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous womenMedicine (Baltimore)84261816148726
- HughesDAElliottPMShahJ2007Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfaHeart54 [Epub ahead of print]
- IchinoseMNakayamaMOhashiT2005Significance of screening for Fabry disease among male dialysis patientsClin Exp Nephrol92283216189631
- ImbriacoMSpinelliLCuocoloA2007MRI characterization of myocardial tissue in patients with Fabry’s diseaseAJR Am J Roentgenol188850317312078
- KikanoGEBrownMT2007Antiplatelet therapy for atherothrombotic disease: an update for the primary care physicianMayo Clin Proc825839817511957
- LidoveOJolyDBarbeyF2007Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literatureInt J Clin Pract6129330217263716
- LinthorstGEHollakCEDonker-KoopmanWE2004Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and betaKidney Int6615899515458455
- MacDermotKDHolmesAMinersAH2001aAnderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJ Med Genet387506011694547
- MacDermotKDHolmesAMinersAH2001bAnderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJ Med Genet387697511732485
- MehtaARicciRWidmerU2004Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome SurveyEur J Clin Invest342364215025684
- MooreDFGeldermanMPFerreiraPA2007Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approachProc Natl Acad Sci USA10480657017470787
- MooreDFKaneskiCRAskariH2007The cerebral vasculopathy of Fabry diseaseJ Neurol Sci2572586317362993
- MooreDFRiesMForgetEL2007Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson diseasePharmacoeconomics25201817335306
- MurrayGJAnverMRKennedyMA2007Cellular and tissue distribution of intravenously administered agalsidase alfaMol Genet Metab903071217188539
- OwensCLRussellSDHalushkaMK2006Histologic and electron microscopy findings in myocardium of treated Fabry diseaseHum Pathol37764816733219
- PastoresGM2003Enzyme therapy for the lysosomal storage disorders: principles, patents, practice and prospectsExpert Opin Ther Patents13115772
- PastoresGM2004Agalsidase alfa (Replagal™): enzyme therapy for Anderson-Fabry diseaseTherapy120311
- PastoresGMBoydECrandallK2007Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal diseaseNephrol Dial Transplant221920517395657
- PastoresGMThadhaniR2002Advances in the management of Anderson-Fabry disease: enzyme replacement therapyExpert Opin Biol Ther23253311890871
- RamaswamiUWendtSPintos-MorellG2007Enzyme replacement therapy with agalsidase alfa in children with Fabry diseaseActa Paediatr96122717187618
- RiesMClarkeJTWhybraC2006Enzyme-replacement therapy with agalsidase alfa in children with Fabry diseasePediatrics1189243216950982
- RolfsABottcherTZschiescheM2005Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective studyLancet3661794616298216
- SchellekensH2005Factors influencing the immunogenicity of therapeutic proteinsNephrol Dial Transplant20Suppl 6vi3915958824
- SchiffmannRAskariHTimmonsM2007Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosingJ Am Soc Nephrol1815768317409308
- SchiffmannRFloeterMKDambrosiaJM2003Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry diseaseMuscle Nerve287031014639584
- SchiffmannRKoppJBAustinHAI2001Enzyme replacement therapy in Fabry disease: a randomized controlled trialJAMA28527434911386930
- SchiffmannRMurrayGJTrecoD2000Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry diseaseProc Natl Acad Sci USA973657010618424
- SchiffmannRRapkiewiczAAbu-AsabM2006Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacementVirchows Arch4483374316315019
- SchiffmannRRiesMTimmonsM2006Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion settingNephrol Dial Transplant213455416204287
- SessaAMeroniMBattiniG2004Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry diseaseSemin Nephrol24532615490423
- ShahJSHughesDASachdevB2005Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry diseaseAm J Cardiol96842616169374
- ShahJSHughesDATayebjeeMH2007Extracellular matrix turnover and disease severity in Anderson-Fabry diseaseJ Inherit Metab Dis30889517160618
- TanakaMOhashiTKobayashiM2005Identification of Fabry’s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patientsClin Nephrol64281716240899
- VanceDEKrivitWSweeleyCC1975Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry’s diseaseJ Biol Chem250811925809441
- van de WeertMJorgensenLHorn MoellerE2005Factors of importance for a successful delivery system for proteinsExpert Opin Drug Deliv210293716296807
- VedderACLinthorstGEHougeG2007Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kgPLoS ONE2e59817622343
- VedderACLinthorstGEvan BreemenMJ2007The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levelsJ Inherit Metab Dis30687817206462
- WarnockDG2007Enzyme replacement therapy and Fabry kidney disease: quo vadisJ Am Soc Nephrol1813687017429046
- WarnockDG2005Fabry disease: diagnosis and management, with emphasis on the renal manifestationsCurr Opin Nephrol Hypertens14879515687833
- WhybraCSchwartingAKriegsmannJ2006IgA nephropathy in two adolescent sisters heterozygous for Fabry diseasePediatr Nephrol211251616838183